FLT3 and acute myeloid leukemia: However, the clinical studies performed in FLT3-mutated R/R AML patients using Iadademstat in association with Gilteritinib have preliminarily shown promising results that need to be extended and confirmed in randomized clinical trials with an appropriate control group.